Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 1Gastrointestinal 1

Conditions

Prostatic Neoplasms 1Liver Neoplasms 1Carcinoma, Hepatocellular 1

Interventions

Cisplatin 1041Cyclophosphamide 973Carboplatin 954Radiotherapy 893Bevacizumab 847Gemcitabine 817pembrolizumab 759Paclitaxel 738Docetaxel 734Oxaliplatin 706Capecitabine 648Fluorouracil 564Rituximab 559Nivolumab 506Dexamethasone 487Etoposide 468Doxorubicin 458Irinotecan 442Drug Therapy 402Leucovorin 377Cytarabine 342Cetuximab 340Lenalidomide 326Trastuzumab 323Pemetrexed 315durvalumab 295Filgrastim 287Magnetic Resonance Spectroscopy 278Temozolomide 275Prednisone 273

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × OTHER × 3-(4-chlorophenyl)-adamantane-1-carboxylic acid (pyridin-4-ylmethyl)amide × Clear all
NCT02939807 2025-04-27

A Phase II Study of ABC294640 as Monotherapy in Patients With Advanced Hepatocellular Carcinoma

Medical University of South Carolina

Phase 2 Withdrawn
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT04207255 2024-09-25

Addition of Opaganib to Androgen Antagonists in Patients With mCRPC

Medical University of South Carolina

Phase 2 Completed
69 enrolled 13 charts
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡